CXCL8 and cancer: Others have hypothesised that polymorphisms in IL8, eNOS,25 and autophagy-related genes26 predict bevacizumab-based therapy response and toxicity, further suggesting that genomic signatures may be used to help oncologists individualise cancer therapy.